Bausch + Lomb Corporation Common Shares (NY:BLCO)

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43...

Bausch + Lomb Corp (NYSE:BLCO) Reports Mixed Q4 2025 Results: Revenue Beat, EPS Miss ↗

February 18, 2026

Via Chartmill

Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue

February 18, 2026

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

February 18, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market hours. Here’s what to look for.

Bausch + Lomb (BLCO) Q4 Earnings: What To Expect

February 16, 2026

Bausch + Lomb’s 24.2% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $16.93 per share. This was partly thanks to its solid quarterly results, and...

Topics World Trade

3 Reasons to Sell BLCO and 1 Stock to Buy Instead

February 09, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

Topics Bankruptcy Stocks

1 Healthcare Stock to Research Further and 2 Facing Headwinds

January 29, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Topics Stocks

3 Stocks Under $50 That Fall Short

January 26, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...

3 Cash-Burning Stocks We’re Skeptical Of

January 22, 2026

Topics Bankruptcy

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

January 20, 2026

Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

January 05, 2026

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

January 02, 2026

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

1 Profitable Stock to Keep an Eye On and 2 We Question

December 17, 2025

Strong operating results did not stop one fund from walking away entirely, raising questions about how much patience volatile healthcare names really command.

Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year ↗

December 17, 2025

Via The Motley Fool

Bausch + Lomb Announces Two Board of Directors Appointments

December 17, 2025

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

December 12, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.2% in the morning session after Citigroup upgraded its rating on the company's shares to Buy from Neutral and raised its price target. The...

Why Bausch + Lomb (BLCO) Stock Is Trading Up Today

December 11, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...

Topics Artificial Intelligence Initial Public Offering

3 Healthcare Stocks We Think Twice About

December 10, 2025

BLCO Stock Still 16% Below IPO — Is Silver Point’s $38.7 Million Bet a Turning Point? ↗

Topics Stocks

December 03, 2025

One fund just made a bold move on an eye-care giant—here’s why it may signal a deeper shift in the company’s long-term trajectory.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Why Bausch + Lomb (BLCO) Stock Is Up Today

December 02, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 4.2% in the morning session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal Weight.". The investment bank...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Topics Economy Initial Public Offering

3 Small-Cap Stocks with Warning Signs

December 01, 2025

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.

3 Cash-Burning Stocks We Approach with Caution

November 23, 2025

Option Care Health, DaVita, Revvity, West Pharmaceutical Services, and Bausch + Lomb Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Topics Economy

Bausch + Lomb to Participate in Citi Global Healthcare Conference

November 18, 2025

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

November 13, 2025

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

Topics Artificial Intelligence Stocks

November 10, 2025

Medical Devices & Supplies - Specialty Stocks Q3 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers

November 10, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - specialty stocks fared in Q3,...

Bausch + Lomb’s third quarter saw a positive market response, as the company posted growth across all major segments and met Wall Street’s revenue expectations. Management highlighted that strong...

5 Revealing Analyst Questions From Bausch + Lomb’s Q3 Earnings Call

November 05, 2025